INS and metabolic dysfunction-associated steatotic liver disease: Glucagon-like peptide (GLP)-1 modulators, thiazolidinedione insulin sensitizers, and sodium-glucose cotransporter (SGLT)-2 inhibitors are among the most promising antidiabetic agents to treat NAFLD [16].